DiaMedica Therapeutics Inc.

NASDAQ:DMAC

4.25 (USD) • At close November 1, 2024
Bedrijfsnaam DiaMedica Therapeutics Inc.
Symbool DMAC
Munteenheid USD
Prijs 4.25
Beurswaarde 181,678,150
Dividendpercentage 0%
52-weken bereik 2.12 - 4.95
Industrie Biotechnology
Sector Healthcare
CEO Mr. Dietrich John Pauls MBA
Website https://www.diamedica.com

An error occurred while fetching data.

Over DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type

Vergelijkbare Aandelen

InflaRx N.V. logo

InflaRx N.V.

IFRX

1.58 USD

Novo Integrated Sciences, Inc. logo

Novo Integrated Sciences, Inc.

NVOS

0.177 USD

Orgenesis Inc. logo

Orgenesis Inc.

ORGS

1.2 USD

Akebia Therapeutics, Inc. logo

Akebia Therapeutics, Inc.

AKBA

1.69 USD

Streamline Health Solutions, Inc. logo

Streamline Health Solutions, Inc.

STRM

2.3 USD

Rain Therapeutics Inc. logo

Rain Therapeutics Inc.

RAIN

1.21 USD

MediWound Ltd. logo

MediWound Ltd.

MDWD

18.37 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)